

Company name Althea Medical

CEO name Lia Ofek Cell

CATEGORY: Medical Devices

SESSIONS • Why does cardiovascular disease remain the number ONE target for MedTech innovation? • Israeli medical contribution to breakthrough science and technology

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Althea Medical was founded in late 2020 by an experienced team of engineers and is currently in the preclinical stage. The product offers a catheter-based solution for acute PE - an often-fatal blockage of the pulmonary arteries by blood clots that migrate from the legs. An effective method of clot removal enables rapid debulking and improved hemodynamic stability for patients.

o Core Technology What is the technology, its uniqueness, and its value proposition? Althea has developed a unique clot aspiration catheter that has various flexibility zones, including an ultra-flexible distal end. This enables an increase in catheter diameter without affecting flexibility. Althea has additionally developed a mechanical clot disruption and capture system which can be controlled by the operator, allowing a one-size-fits-all device for treatment of a wide range of clot types and sizes.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential.

Discuss milestones, potential collaborations, and partnerships. Each year, 1.1M people present with pulmonary embolism worldwide, roughly half of them being characterized as intermediate/high risk patients. Althea Medical's Pulmonary Embolectomy device is intended to treat this patient population, representing a market size of over \$1B.

o Business Strategy Briefly describe how the company will apply its core technology, generate shortterm and long-term revenues. Following FIH study in Europe that will be followed by IDE in the US, we expect sales to begin in 2028. o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans The company is currently completing its preclinical testing and intends to start a First in Human study later this year. In addition, the company is working on extending its product portfolio and increasing its technology footprint.